ISM001-055 Phase IIa Trial — AI-Designed Therapeutic Achieves Clinical Milestone

Insilico Medicine's AI-designed therapeutic ISM001-055, an idiopathic pulmonary fibrosis treatment targeting the TNIK pathway, achieved positive Phase IIa clinical trial results. ISM001-055 was designed and brought to clinical trials using agentic AI workflows, representing one of the most advanced examples of AI-designed drugs reaching clinical validation. The drug was discovered using Insilico's generative chemistry platform and validated through AI-powered clinical trial design. The positive Phase IIa results validate the end-to-end AI drug discovery approach, from target identification through molecule generation to clinical development. This milestone positions AI-designed drugs as viable commercial therapeutics.